Versartis, Inc. (VSAR) Completes Enrollment in Phase III VELOCITY Trial of Somavaratan for the Treatment of Pediatric GHD
In a recent news release, Versartis, Inc. (NASDAQ: VSAR), an endocrine-focused biopharmaceutical company, announced the completion of enrollment for its phase III VELOCITY trial of somavaratan, a long-acting form of recombinant human growth hormone (rhGH) currently being evaluated for the treatment of pediatric growth hormone deficiency (GHD). The randomized, open-label registration trial will focus on pre-pubertal children with GHD who are naïve to treatment. Moving forward, the 137 enrolled patients will be followed for the primary trial endpoint of height velocity at 12 months, along with safety and pharmacodynamics secondary endpoints. Versartis expects to present top-line results from the VELOCITY…